Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Acute Respiratory Distress Syndrome (ARDS) Market Revenue Growth Supported By A CAGR Of 2.42% Through 2030
The market for acute respiratory distress syndrome (ARDS) has experienced substantial expansion lately, projected to climb from $1.41 billion in 2025 to $1.56 billion by 2026, reflecting a compound annual growth rate of 10.5%. This upward trajectory in the historical period is largely due to a surge in respiratory infections, enhanced intensive care unit capacity within hospitals, greater dissemination of ARDS management guidelines, the restricted accessibility of sophisticated ventilation technology, and the increasing implementation of palliative care strategies.
The global market for Acute Respiratory Distress Syndrome (ARDS) is poised for significant expansion over the coming years, projecting a valuation of $2.42 billion by 2030, driven by a compound annual growth rate of 11.7%. This anticipated growth is underpinned by several key factors, including innovations in mechanical ventilation and extracorporeal membrane oxygenation (ECMO) technologies, heightened research and development efforts in ARDS therapies, the expansion of critical care facilities worldwide, increased investment in tailored patient management approaches, and the rising incidence of severe pneumonia and sepsis. Emerging trends expected to shape the market during this period involve the growing utilization of mechanical ventilation and ECMO devices, a higher prevalence of ARDS stemming from COVID-19 and other respiratory ailments, the increased deployment of sophisticated diagnostic tools for earlier identification, the expansion of critical care and intensive care unit capacities, and a pronounced emphasis on individualized and supportive care strategies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp
#Acute Respiratory Distress Syndrome (ARDS) Market Demand Drivers Creating New Revenue Opportunities
A rise in respiratory ailments is anticipated to fuel the expansion of the acute respiratory distress syndrome (ARDS) market. Respiratory illnesses encompass a range of conditions affecting the respiratory tract, such as the airways and lungs, and can lead to breathing challenges. The growing prevalence of these conditions, exemplified by COVID-19, stands as a primary catalyst for the advancement of the ARDS market. Consequently, as more individuals contract respiratory illnesses, the need for treatments and therapeutic interventions for ARDS is projected to escalate, thereby stimulating market growth. For example, data from the National Asthma Council in Australia, a non-profit entity, indicated that in 2023, the nation witnessed 474 fatalities attributed to asthma, with 325 being female and 149 male. This number closely mirrors the 473 asthma-related deaths recorded in 2022, underscoring a stable pattern in asthma mortality across these two years. Thus, the escalating incidence of respiratory illnesses is demonstrably contributing to the growth trajectory of the ARDS market.
Acute Respiratory Distress Syndrome (ARDS) Market Segment Analysis And Revenue Opportunities
The acute respiratory distress syndrome (ards) market covered in this report is segmented –
1) By Type: Diagnosis, Treatment
2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes
3) By Severity: Mild, Moderate, Severe
4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users
Subsegments:
1) By Diagnosis: Imaging Tests, Blood Tests
2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care
Acute Respiratory Distress Syndrome (ARDS) Market Trends Driving Strategic Industry Expansion
Key players in the acute respiratory distress syndrome market are concentrating their efforts on creating sophisticated immune-modulating treatments to boost patient survival rates and mitigate inflammation. These immune modulators function by re-establishing equilibrium within the immune system, specifically addressing flawed inflammatory processes rather than broadly depressing immune responses. A prime example is BioAegis Therapeutics, a US clinical-stage entity, which obtained FDA Fast Track designation in June 2025 for rhu-pGSN, their experimental therapy aimed at ARDS. This treatment’s mechanism involves restoring levels of gelsolin, an essential protein for immune regulation, thereby overseeing the activation of the NLRP3 inflammasome, improving the body’s ability to clear pathogens, eliminating harmful actin and inflammatory substances, and controlling macrophage behavior. Currently undergoing assessment in a comprehensive global Phase 2b study involving 600 participants with moderate to severe ARDS, rhu-pGSN might also become accessible via the FDA’s Expanded Access or Compassionate Use pathways. The Fast Track status facilitates a more streamlined regulatory review process, allows for the submission of marketing applications in stages, and qualifies the therapy for priority review, which could significantly shorten its journey to market and present a groundbreaking treatment avenue for individuals facing dire medical circumstances with few other options.
Acute Respiratory Distress Syndrome (ARDS) Market Leading Players Shaping Industry Direction
Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy
Access The Complete Acute Respiratory Distress Syndrome (ARDS) Market Report:
Acute Respiratory Distress Syndrome (ARDS) Market Geographic Landscape: Which Region Dominates Industry Growth?
North Americawas the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in the acute respiratory distress syndrome (ards) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
